By Josh Beckerman

 

CureVac NV shares fell 52% to $45.45 in after-hours trading as the company reported unfavorable interim data from a Covid-19 vaccine clinical trial.

"In the unprecedented context of at least 13 variants circulating within the study population subset assessed at this interim analysis, CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity and did not meet prespecified statistical success criteria," CureVac said.

The HERALD study, conducted by CureVac in conjunction with Bayer, enrolled about 40,000 people in 10 countries in Latin America and Europe.

 

Write to Josh Beckerman at josh.beckerman@wsj.com

 

(END) Dow Jones Newswires

June 16, 2021 17:40 ET (21:40 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Bayer (XE:BAYN)
Historical Stock Chart
From Aug 2021 to Sep 2021 Click Here for more Bayer Charts.
Bayer (XE:BAYN)
Historical Stock Chart
From Sep 2020 to Sep 2021 Click Here for more Bayer Charts.